These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11488204

  • 1. [Effect of PSA nadir and the time to nadir in the disease-free period in localized prostatic carcinoma treated with radical radiation].
    Cambeiro M, Azinovic I, Villafranca E, Moreno-Jiménez M, Cañón R, Aristu JJ, Beltrán C, López-Picazo JM, Fernández J, Rebollo J.
    Rev Med Univ Navarra; 2001; 45(1):20-8. PubMed ID: 11488204
    [Abstract] [Full Text] [Related]

  • 2. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 3. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A.
    Prog Urol; 2002 Jun 15; 12(3):421-8. PubMed ID: 12189749
    [Abstract] [Full Text] [Related]

  • 4. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer.
    Nickers P, Albert A, Waltregny D, Deneufbourg JM.
    Int J Radiat Oncol Biol Phys; 2006 May 01; 65(1):73-7. PubMed ID: 16503381
    [Abstract] [Full Text] [Related]

  • 7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
    Almeras C, Zerbib M, Eschwege F, Debré B.
    Prog Urol; 2002 Apr 01; 12(2):219-25. PubMed ID: 12108335
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1430-9. PubMed ID: 16765527
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE.
    Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1350-6. PubMed ID: 19515504
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, Hinkelbein W, Budach V, Loening SA.
    Eur Urol; 2005 Apr 01; 47(4):441-8. PubMed ID: 15774239
    [Abstract] [Full Text] [Related]

  • 16. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 17. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 01; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 18. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 19. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
    Cavanaugh SX, Kupelian PA, Fuller CD, Reddy C, Bradshaw P, Pollock BH, Fuss M.
    Cancer; 2004 Jul 01; 101(1):96-105. PubMed ID: 15221994
    [Abstract] [Full Text] [Related]

  • 20. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.